News archive
Showing 755 results
February 2013
-
Media Release
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
- Phase III study published in NEJM today and to be presented tomorrow met primary endpoint in moderate-to-severe chronic idiopathic urticaria (CIU)- CIU can be a serious, debilitating form of hives… -
Media Release
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
-
Media Release
Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
- Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation- Approval based on… -
Media Release
Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
January 2013
-
Media Release
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
-- Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate1-- Patients with NTDT accumulate… -
Media Release
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
December 2012
-
Media Release
NEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis
- Endpoints met in two Phase III trials, including substantial symptom relief in 84% of systemic juvenile idiopathic arthritis (SJIA) patients treated with ACZ885 in trial-11- SJIA patients treated… -
Media Release
NEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis
-
Media Release
Multimedia Assets: Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
- As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease(1)- In the Phase III trial, most patients… -
Media Release
Multimedia Assets: Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media Release
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
- As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease(1)- In the Phase III trial, most patients… -
Media Release
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder